2026 Q1 -tulosraportti
Vain PDF
76 päivää sitten
0,8572 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 19.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 20.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 22.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·6.7. · Muokattu.........so Jens Eriksson has just done it again🙄 Writes on Coegin Pharma's profile on Linkedin about what a great achievement it is that their partner in Poland, Mercapharm, has just launched their "Trichobalance™, powered by Follicopeptide®" via dermatological clinics in Poland. .....and then the question arises again - again - again - again - again!? If it really is such a great achievement and significant for Coegin, why doesn't the fool then issue a Company Announcement via the Stock Exchange? Good heavens, how that company underJens Eriksson's leadership is such a scam and a rip-off joint🙄 Check Linkedin yourself, you'll find the story there...........
·16.6.2 positive press releases in 2 days. Then they probably need money soon. Expect a share issue.@ Dengamlefisker: If my memory doesn't fail me completely, you & I have on several occasions expressed our views on Coegin Pharma AB in general and CEO Jens Eriksson in particular - and I sense that we are still 100% of the same opinion regarding the continued circus performance the company offers as its only entertainment. That being said, (and no, I still have NADA confidence in the company) there is now one single valid data point in the case to test, to see if 'the bird on the roof is actually growing wings'. The data point is an excerpt from a company announcement I have inserted in this thread above. Provided that CEO Lars Skjøth, Hårklinikken has actually stated as mentioned, this should result in a product launch during H2 2026. The announcement is radically new in the sense that it has been made by a third party, namely Hårklinikken - and thus is not just number 733 tall tale from Jens Eriksson, Coegin Pharma AB. This makes the announcement a data point that can be tested to see if the case in general is moving forward. So, as an investor, one can now stand on the sidelines and await that launch. It would be utterly insane, as in completely psychopathic brain-dead, to buy into the case now - and should the launch really take place during H2 2026 - probably supplemented by a new share issue from Coegin Pharma AB - then one can at that time decide for oneself whether one thinks it is a good investment. Coegin Pharma AB's entire future rests on Hårklinikken's intention to launch their hair product - no more, no less.
·6.5.PP405 (or PP-405) is a promising, topical, non-hormonal drug candidate under development by Pelage Pharmaceuticals for the treatment of androgenetic alopecia (hereditary hair loss). By inhibiting a mitochondrial protein (MPC), it activates dormant stem cells in hair follicles, which can restore hair growth. Results from Phase 2a studies have shown positive effect, and the treatment is being studied as a daily gel.
·29.4.The report they presented was not great. They are still burning a lot of cash and revenue is very small. Auditor with a 'going concern' remark. That does not look good and Coegin only expects liquidity into Q3 2026.New hårprodukr was supposed to be launched in April. That didn't happen then. Coegin has apparently "forgotten" to inform about that. Gents now writes that it will be in May. Perhaps the launch will be combined with them having to beg for more money from the shareholders.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
76 päivää sitten
0,8572 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·6.7. · Muokattu.........so Jens Eriksson has just done it again🙄 Writes on Coegin Pharma's profile on Linkedin about what a great achievement it is that their partner in Poland, Mercapharm, has just launched their "Trichobalance™, powered by Follicopeptide®" via dermatological clinics in Poland. .....and then the question arises again - again - again - again - again!? If it really is such a great achievement and significant for Coegin, why doesn't the fool then issue a Company Announcement via the Stock Exchange? Good heavens, how that company underJens Eriksson's leadership is such a scam and a rip-off joint🙄 Check Linkedin yourself, you'll find the story there...........
- ·16.6.2 positive press releases in 2 days. Then they probably need money soon. Expect a share issue.@ Dengamlefisker: If my memory doesn't fail me completely, you & I have on several occasions expressed our views on Coegin Pharma AB in general and CEO Jens Eriksson in particular - and I sense that we are still 100% of the same opinion regarding the continued circus performance the company offers as its only entertainment. That being said, (and no, I still have NADA confidence in the company) there is now one single valid data point in the case to test, to see if 'the bird on the roof is actually growing wings'. The data point is an excerpt from a company announcement I have inserted in this thread above. Provided that CEO Lars Skjøth, Hårklinikken has actually stated as mentioned, this should result in a product launch during H2 2026. The announcement is radically new in the sense that it has been made by a third party, namely Hårklinikken - and thus is not just number 733 tall tale from Jens Eriksson, Coegin Pharma AB. This makes the announcement a data point that can be tested to see if the case in general is moving forward. So, as an investor, one can now stand on the sidelines and await that launch. It would be utterly insane, as in completely psychopathic brain-dead, to buy into the case now - and should the launch really take place during H2 2026 - probably supplemented by a new share issue from Coegin Pharma AB - then one can at that time decide for oneself whether one thinks it is a good investment. Coegin Pharma AB's entire future rests on Hårklinikken's intention to launch their hair product - no more, no less.
- ·6.5.PP405 (or PP-405) is a promising, topical, non-hormonal drug candidate under development by Pelage Pharmaceuticals for the treatment of androgenetic alopecia (hereditary hair loss). By inhibiting a mitochondrial protein (MPC), it activates dormant stem cells in hair follicles, which can restore hair growth. Results from Phase 2a studies have shown positive effect, and the treatment is being studied as a daily gel.
- ·29.4.The report they presented was not great. They are still burning a lot of cash and revenue is very small. Auditor with a 'going concern' remark. That does not look good and Coegin only expects liquidity into Q3 2026.New hårprodukr was supposed to be launched in April. That didn't happen then. Coegin has apparently "forgotten" to inform about that. Gents now writes that it will be in May. Perhaps the launch will be combined with them having to beg for more money from the shareholders.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 19.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 20.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 22.5.2025 |
2026 Q1 -tulosraportti
Vain PDF
76 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 19.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 20.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 22.5.2025 |
0,8572 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·6.7. · Muokattu.........so Jens Eriksson has just done it again🙄 Writes on Coegin Pharma's profile on Linkedin about what a great achievement it is that their partner in Poland, Mercapharm, has just launched their "Trichobalance™, powered by Follicopeptide®" via dermatological clinics in Poland. .....and then the question arises again - again - again - again - again!? If it really is such a great achievement and significant for Coegin, why doesn't the fool then issue a Company Announcement via the Stock Exchange? Good heavens, how that company underJens Eriksson's leadership is such a scam and a rip-off joint🙄 Check Linkedin yourself, you'll find the story there...........
- ·16.6.2 positive press releases in 2 days. Then they probably need money soon. Expect a share issue.@ Dengamlefisker: If my memory doesn't fail me completely, you & I have on several occasions expressed our views on Coegin Pharma AB in general and CEO Jens Eriksson in particular - and I sense that we are still 100% of the same opinion regarding the continued circus performance the company offers as its only entertainment. That being said, (and no, I still have NADA confidence in the company) there is now one single valid data point in the case to test, to see if 'the bird on the roof is actually growing wings'. The data point is an excerpt from a company announcement I have inserted in this thread above. Provided that CEO Lars Skjøth, Hårklinikken has actually stated as mentioned, this should result in a product launch during H2 2026. The announcement is radically new in the sense that it has been made by a third party, namely Hårklinikken - and thus is not just number 733 tall tale from Jens Eriksson, Coegin Pharma AB. This makes the announcement a data point that can be tested to see if the case in general is moving forward. So, as an investor, one can now stand on the sidelines and await that launch. It would be utterly insane, as in completely psychopathic brain-dead, to buy into the case now - and should the launch really take place during H2 2026 - probably supplemented by a new share issue from Coegin Pharma AB - then one can at that time decide for oneself whether one thinks it is a good investment. Coegin Pharma AB's entire future rests on Hårklinikken's intention to launch their hair product - no more, no less.
- ·6.5.PP405 (or PP-405) is a promising, topical, non-hormonal drug candidate under development by Pelage Pharmaceuticals for the treatment of androgenetic alopecia (hereditary hair loss). By inhibiting a mitochondrial protein (MPC), it activates dormant stem cells in hair follicles, which can restore hair growth. Results from Phase 2a studies have shown positive effect, and the treatment is being studied as a daily gel.
- ·29.4.The report they presented was not great. They are still burning a lot of cash and revenue is very small. Auditor with a 'going concern' remark. That does not look good and Coegin only expects liquidity into Q3 2026.New hårprodukr was supposed to be launched in April. That didn't happen then. Coegin has apparently "forgotten" to inform about that. Gents now writes that it will be in May. Perhaps the launch will be combined with them having to beg for more money from the shareholders.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt